Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celotix is a topical corticosteroid lotion marketed by Alicia Healthcare, an Indian pharmaceutical company. The formulation contains clobetasol propionate, a very high-potency (Class I) synthetic glucocorticoid. It is indicated for the short-term treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses, such as psoriasis and recalcitrant eczemas. Clobetasol propionate acts as an agonist at the glucocorticoid receptor, leading to the inhibition of inflammatory pathways by inducing lipocortins and suppressing the release of arachidonic acid. As a commercial generic product, Celotix is distributed through a franchise-based business model in the Indian market.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Celotix.